Main Products/ Services/ Pipelines & Platforms
• BRM421 ◦ First-in-class treatment for Dry Eye Syndrome (DES) ◦ Safe and effective therapy with fast relief ◦ Expect to obtain the result of a Phase 3 trial by the end of 2023 • BRM424 ◦ Orphan drug for Neurotrophic Keratitis ◦ Phase 2 ready • PDSP technology platform ◦ Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) platform ◦ Repairs damaged tissues by promoting stem cell proliferation and differentiation ◦ Early-onset potential in various disease animal models ◦ Low immunogenicity, no endotoxin risk, and high pharmaceutical stability
Business Interests
• Out-Licensing • Co-development • Investment
Contact Info
Yichun Maria Chen
VP of Business Development
+886-2-2659-8586#110
yichun.chen@brimbiotech.com
Yilun Chiang
Business Development Manager
+886-2-2659-8586#120
yilun.chiang@brimbiotech.com